Our investment case for West Pharmaceutical Services is clear: West sits in a uniquely strong position within a structurally growing industry, with the potential to create huge sustainability gains for the world. We believe that there are substantial barriers in the way of competitors who would encroach on West’s business. The first relates to economics. Because a stopper is so cheap, customers have little incentive even to consider the products of other suppliers. We believe that West is likely to benefit from two big tailwinds in the coming years. The first is regulation. Europe’s Annex 1 rules, tightened in 2023, demand far ‘cleaner’ packaging products. High-performing companies like West are likely to be the biggest beneficiaries of these regulatory shifts. At current prices, we think the company represents a tremendous opportunity.

West Pharmaceutical is a leading provider of injectable drug packaging solutions. The company delivered a strong quarter, with revenue and earnings exceeding expectations, driven by accelerating demand for high-value products and GLP-1 components. Margin expansion improved as the mix shifted toward higher margin offerings, and management raised full-year guidance, reflecting better operating execution and easing capacity constraints. Recent results highlight continued strength in both GLP-1 and non-GLP-1 components, indicating robust demand and a positive outlook for the business.

West Pharmaceutical Services (WST) is a leading producer of packaging and components for injectable drug delivery devices. The company is expected to benefit from tailwinds such as the growing usage of GLP-1 drugs and advancements in drug development, alongside a push to reshore drug manufacturing. Although WST has historically traded at a premium, its shares have de-rated to a more reasonable valuation of approximately 23x 2026 EBITDA. This valuation appears justified given WST's solid growth, deep regulatory-driven competitive advantages, and the potential for accelerated growth in the coming years.

West Pharmaceutical Services (WST), a medical supplies company specializing in elastomer-based solutions, continued to rebound from its volatile start to 2025. On the heels of a strong earnings report that exceeded consensus expectations and the hiring of a new CFO, the stock moved 20% higher during the quarter. The company has delivered consecutive quarters of revenue growth in its high-value product segment, while inventory destocking headwinds continue to ease.

West Pharmaceutical Services’ (WST) shares continued to recover from a volatile start to 2025 after a soft initial outlook. Second-quarter results showed improvement in the core business, restoring management credibility and supporting the view that long-term earnings potential exceeds current consensus expectations.

West Pharmaceutical Services designs and manufactures advanced integrated containment and delivery systems for injectable drugs and healthcare products globally. Their components are essential for the safe and effective delivery of injectable medicines, creating significant pricing power and durability. Despite a nearly 40% stock sell-off due to short-term concerns, we believe there is nothing structurally wrong with West. The company remains well-positioned for long-term recovery and sustained growth, driven by increasing use of biologics and participation in the GLP-1 market.

West Pharmaceutical Services, Inc. is a leading manufacturer of drug packaging components and delivery systems for injectable drugs. Although management expects the core business to perform well in 2025, shares fell on setbacks in two other areas of the business. First, West declined to renew two contracts in its contract manufacturing business due to unfavorable economics. Second, some high margin 2024 revenue with a large customer for West’s Smart Dose On-Body Delivery System will not repeat in 2025. As a result, 2025 earnings guidance was materially below investor expectations. While we are disappointed with the re-set, we think earnings can grow at a mid-teens rate from this new level.